Danaher's Strategic Abcam Deal Boosts Growth at a Reasonable Price: Analyst
Portfolio Pulse from Vandana Singh
Danaher Corporation (DHR) has agreed to acquire Abcam plc (ABCM) for $24.00 per share in cash, a total enterprise value of ~$5.7 billion. The deal is expected to close in mid-2024 and will be funded using cash on hand and proceeds from the issuance of commercial paper. Analysts from William Blair believe the acquisition will promote growth and bolster margins for Danaher, and allow it to penetrate the proteomics reagents market, where Thermo Fisher Scientific Inc (TMO) and Merck Millipore have strong positions.
August 29, 2023 | 7:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Thermo Fisher Scientific Inc is mentioned as a key player in the proteomics reagents market, which Danaher aims to penetrate through its acquisition of Abcam.
While Thermo Fisher is mentioned as a key player in the proteomics reagents market, the news does not directly impact the company. However, it could face increased competition from Danaher following the acquisition.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Abcam is being acquired by Danaher for $24.00 per share in cash, a total enterprise value of ~$5.7 billion.
The acquisition by Danaher is expected to have a positive impact on Abcam's stock price, given the agreed price of $24.00 per share.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Danaher's acquisition of Abcam is expected to promote growth and bolster margins, and allow it to penetrate the proteomics reagents market.
The acquisition is seen as a strategic move that will allow Danaher to penetrate the proteomics reagents market and boost its growth and margins. The timing of the acquisition is also seen as positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100